Metropolis Healthcare Ltd. · NSE:METROPOLIS

Metropolis Healthcare — Investor Presentation (August 2026)

28 slides from Metropolis Healthcare's investor presentation, Aug 27, 2026

  1. Slide 1: Stock exchange cover letter: Investor Presentation

    Ref: MHL/Sec&Legal/2026-27/42 August 27, 2026 To, BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are

  2. Slide 2: Investor & Analyst Meet 2026

    Investor & Analyst Meet 2026 Strengthen the core. Expand adjacencies. Compound shareholder value. Diagnostics trusted by Doctors and Patients alike Metropolis Healthcare Limited

  3. Slide 3: Safe Harbour

    SAFE HARBOUR Safe Harbour This presentation has been prepared by Metropolis Healthcare Limited for information purposes only. It does not constitute a prospectus, offering circular or offering memorandum, and is not a recommendation regarding any securities of the Company. It may contain forward-loo

  4. Slide 4: A strong national network and legacy built over 45 years

    METROPOLIS AT A GLANCE A strong national network and legacy built over 45 years 209 / 5,000 750 ₹1,646 Cr Laboratories and Towns in India, plus FY26 revenue across B2C collection centres five international markets and B2B 30,000 prescribing specialists, and every leading hospital chain is a clien

  5. Slide 5: Majority market is unorganised - and three shifts broadening it

    MARKET CONTEXT Majority market is unorganised - and three shifts broadening it The shift to organised players is real, but gradual. 37% 48% $11  28.5 Bn 60% Indian diagnostics market to 2034, Of mortality from non-communicable at 11% CAGR 15% disease Unorganise d / standa lone Or ganise d cha ins

  6. Slide 6: Specialty is not an automatic win

    SCIENTIFIC CAPABILITY  THE COMPETITIVE MOAT Specialty is not an automatic win “Instruments are easy to add. The confidence of WHAT CANNOT BE REPLICATED specialists is earned over time.” QUICKLY Interpretation takes years to build, and it is what clinicians buy. 35 NABL labs and 2 CAP accredited ge

  7. Slide 7: Three years of broad-based, profitable growth

    PERFORMANCE · FY2426 Three years of broad-based, profitable growth Group basis, ₹ Crore. REVENUE FROM OPERATIONS EBITDA PROFIT AFTER TAX ₹ Crore ₹ Crore ₹ Crore 1,646 401 191 1,331 325 161 1,190 285 128 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 17.6% CAGR · FY26 23.6% 18.6% CAGR · FY26 23% 

  8. Slide 8: Promoter led, professionally driven

    LEADERSHIP Promoter led, professionally driven A leadership team built for the next level of growth. Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Founder & Non – Executive Promoter & Executive Managing Director Non - Independent Director Chairperson Sameer Patel Avadhut Joshi Diya Suri Dr. Kir

  9. Slide 9: Talent is the enabler across

    ENABLER · PEOPLE AND TALENT Talent is the enabler across Leadership, a training pipeline and a deep clinical bench. LEADERSHIP AND SCALE DOCTORS AND SCIENTIFIC TALENT Leadership strengthened at CXO and CXO1 The bench behind the specialty menu Over 6,000 professionals, 44% of them 30,000 prescribin

  10. Slide 10: Board, governance framework and shareholding

    GOVERNANCE · BOARD AND SHAREHOLDING Board, governance framework and shareholding Board composition, governance framework and the shareholding structure. 10 5 48.9% 46.2% Directors on the Board Independent directors, Promoter and promoter Institutional holding, FII one a woman group holding plus DII

  11. Slide 11: Metropolis, Our Scientific Capabilities and growth

    AV Metropolis, Our Scientific Capabilities and growth 10

  12. Slide 12: Metropolis – Way forward

    STRATEGY Metropolis – Way forward OUR STRATEGIC IDENTITY A technology-led and scientifically differentiated company, consistently delivering profitable growth and sustained value creation for stakeholders. 01 02 03 04 05 Lead with Differentiate Compound Deliver the Strong Technology Scientifically P

  13. Slide 13: Growth engines

    STRATEGY Growth engines Capital goes to five growth engines, supported by two enablers. 01 02 03 04 05 Network TruHealth Specialty Technology Inorganic Scaling to 1,000 Wellness, Advanced testing Digital platforms, Selective, aligned stores, adding new radiology and to 45% of revenue, automation and

  14. Slide 14: Growth accelerates on the network we have already built

    01 GROWTH · NETWORK AND ACCELERATION Growth accelerates on the network we have already built Deepening 750 towns and doing more from every site. 750  1,000 241 → 351 100 Own centres over three years Centre-to-lab ratio, from 201 in FY21 Mini-hubs - 50 upgrades, 50 new builds Beyond diagnostics

  15. Slide 15: Both channels growing, with different jobs to do

    01 NETWORK & CHANNELS Both channels growing, with different jobs to do 57% 43% 26% B2C share of revenue B2B share of revenue From Tier 3 and smaller towns B2C  WHAT NEXT B2B  WHAT NEXT ● 1,000 own stores by FY29, beyond pathology into vitals, ● Core oncology and genomics menu cross-sold diet and c

  16. Slide 16: TruHealth is on its way to a quarter of revenue

    02 GROWTH · TRUHEALTH & ADJACENCIES TruHealth is on its way to a quarter of revenue Preventive bundles lift ticket size and bring patients back on a schedule. 18%  25% ₹2,500 In line 40% TruHealth share of revenue TruHealth ticket size, at Wellness margins against Growth in radiology- over three

  17. Slide 17: Specialty from 40% to ~45% of revenue

    03 GROWTH · SPECIALTY Specialty from 40% to ~45% of revenue By taking the Core oncology and genomics menu to the national network. 40% → 45% 2,200 347  36 17% Specialty share of revenue Specialty tests in the menu Tests added in FY26 and Specialty revenue growth over three years Q1 FY27 in Q1 FY

  18. Slide 18: Genomics is where our specialty base gives us the right to win

    03 SCIENCE · GENOMICS Genomics is where our specialty base gives us the right to win Integrated diagnostics - biomarkers and genomics, read together. 2x 23 yrs 2 Fastest Genomics portfolio growth Acceleration from the Core CAP-accredited genomics Growing segment within in the past year acquisition

  19. Slide 19: One engine - digital on the front end, automation in the labs

    04 GROWTH · TECHNOLOGY · DIGITAL AND CUSTOMER EXPERIENCE One engine - digital on the front end, automation in the labs Every journey getting simpler, for patients and for doctors. THE METROPOLIS APP 25% 40% 30,000 Digital share of revenue, from Of B2C revenue from self- Specialists on the partner z

  20. Slide 20: Operational excellence through digital transformation

    04 GROWTH · TECHNOLOGY · AUTOMATION AND AI Operational excellence through digital transformation Reducing manual effort, improving workflow, strengthening operational control. AI led Workflow Faster Sample Journey Process Optimisation Reliable Digital Automation Platforms AI ticket resolution, Digit

  21. Slide 21: M&A adds capability, geography and scale - to a repeatable playbook

    05 GROWTH · INORGANIC · M&A M&A adds capability, geography and scale - to a repeatable playbook Core is the benchmark, not the exception 5 2x 4 quarters 18% Acquisitions integrated - Revenue multiple paid for From 2% EBITDA to high North India share of Hitech, Core, DAPIC, Core single digit revenu

  22. Slide 22: International: leading positions across five markets

    INTERNATIONAL International: leading positions across five markets Profitable and self-funding 5 No. 1 Top 3 Nil Countries, principally in Market position in two Position in every market Incremental capital Africa markets contemplated over FY27 29 Revenue and EBITDA both grew, helped by specialised

  23. Slide 23: Guidance of 14–15% assumes no price increase. Q1 delivered 17%

    FY27 OUTLOOK Guidance of 14–15% assumes no price increase. Q1 delivered 17% Q1 is ahead of the trajectory. 1415% 100150 bps ₹450 Cr 25.2% Full-year revenue EBITDA margin Q1 FY27 revenue Q1 FY27 EBITDA margin growth guidance improvement guided 17% YoY 210 bps YoY THE LEVERS BEHIND IT B2C led the

  24. Slide 24: Revenue to grow faster than the preceding three years

    THE THREEYEAR PLAN Revenue to grow faster than the preceding three years Five drivers behind the step up in growth. 01 02 03 04 05 Better network Faster Tier 3 Higher specialty Bolt on Stable volumes utilisation growth growth acquisitions in leadership cities More from Deeper reach Advanced Selecti

  25. Slide 25: Five levers take margin from 24.4% toward 27–28%

    EFFICIENCY AND PRODUCTIVITY Five levers take margin from 24.4% toward 27–28% 01 Specialty & digital mix Premiumisation through Specialty, genomics and digital mix. 02 Lab & centre density Centre-to-lab ratio from 241 to 351. Common menu, equipment, reagents and TAT; vendor consolidation 03 Platfor

  26. Slide 26: Improving balance sheet efficiency

    FINANCIAL AGENDA Improving balance sheet efficiency WORKING CAPITAL ASSET EFFICIENCY AND CASH ALLOCATION ● Receivables automated end to end ● Capex held light @ 4% of the revenue ● Supply chain digitised with vendors ● Rising asset turns on the same estate ● Higher share of digital and cash collecti

  27. Slide 27: Volume drives growth, Utilisation drives margin

    THREE TAKEAWAYS Volume drives growth, Utilisation drives margin 01 02 03 Growth is volume-led Margin comes from Capital now compounds utilisation Outlook CAGR of 1415% Q1 Margin improvement through Improve ROCE through FY27 grew 17% on 10% operating leverage, higher utilisation and low patient and

  28. Slide 28: Thank You

    Thank You F OR F U R T H E R INF OR MA T ION Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN  L73100MH2000PLC192798 CIN  U74140MH2010PTC204285 Mr. Kamlesh Kulkarni - Head, Legal & Mr. Sagar Shroff / Mr. Shogun Jain Secretarial 91 98205 19303 / 91 77383 77756 secretarial@metrop

Metropolis Healthcare — Investor Presentation (August 2026) on 6ix